Advertisement

Carbamazepin, eine Substanz im Grenzgebiet von Neurologie und Psychiatrie

  • D. Schmidt
Conference paper

Zusammenfassung

Carbamazepin (CBZ), ein trizyklisches Aminostilbenderivat, wurde 1957 von Schindler und Blattner synthetisiert und 1963 in Europa als Antiepileptikum zur Behandlung komplexer fokaler Anfälle und generalisierter tonisch-klonischer Anfälle eingeführt. Carbamazepin ist ein Mittel der ersten Wahl zur Behandlung fokaler Anfälle aufgrund seiner im Vergleich ausgezeichneten Wirksamkeit und der relativ niedrigen Nebenwirkungsrate sowie, zumindest bei einigen Patienten, seiner positiven Wirkung auf Stimmung und Verhalten. Weiter ist Carbamazepin ein Mittel der ersten Wahl zur antineuralgischen Therapie bei paroxysmalen Schmerzen, z.B. bei Trigeminus- und anderen Hirn-nervenneuralgien, und bestimmten Polyneuropathien. Schließlich wird Carbamazepin aufgrund seiner antidepressiven und antimanischen Wirkung in der Behandlung psychiatrischer Erkrankungen eingesetzt, vor allem Manien und uni- oder bipolaren Depressionen sowie in der Rezidivprophylaxe manischer und depressiver Phasen bei bi- und unipolaren affektiven Psychosen. In dieser knappen Übersicht wird überwiegend auf die neurologischen und speziell die antiepileptischen Anwendungen von Carbamazepin eingegangen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Aguglia U, Zappia M, Quattrone A (1987) Carbamazepine-induced nonepileptic myoclonus in a child with benign epilepsy. Epilepsia 28: 515–518PubMedCrossRefGoogle Scholar
  2. 2.
    Aldenkamp AP, Alpherts WCJ, Moerland MC, Ottevanger N, van Parys JAP (1987) Controlled release carbamazepine: cognitive side effects in patients with epilepsy. Epilepsia 28: 507–514PubMedCrossRefGoogle Scholar
  3. 3.
    Andrewes DG, Bullen TG, Tomlinson L, Elwes RDC, Reynolds EH (1986) A comparative study of the cognitive effects of phenytoin and carbamazepine in new referrals with epilepsy. Epilepsia 27: 128–134PubMedCrossRefGoogle Scholar
  4. 4.
    Asmark H, Wiholm B (1990) Epidemiology of adverse reactions to carbamazepine as seen in a spontaneous reporting system. Acta Neurol Scand 81: 131–140CrossRefGoogle Scholar
  5. 5.
    Bayer A (1991) Retinale Funktionsstörungen bei Patienten unter antikonvulsiver Therapie. Dissertation, Universität TübingenGoogle Scholar
  6. 6.
    Bayer A, Zrenner E, Paulus W (1990) Empfindliche sinnesphysiologische Testmethoden für okuläre Nebenwirkungen von Medikamenten am Beispiel von Antiepileptika. Fortschr Ophtalmol 14: 328–329Google Scholar
  7. 7.
    Benassi E, Bo GP, Cocito L, Maffini M, Loeb C (1987) Carbamazepine and cardiac conduction disturbances. Ann Neurol 22: 280–281PubMedCrossRefGoogle Scholar
  8. 8.
    Bertollini R, Kallen B, Mastroiacovo P, Robert E (1987) Anticonvulsant drugs in monotherapy: effect on the fetus. Eur J Epidemiol 3: 164–171PubMedCrossRefGoogle Scholar
  9. 9.
    Brodie MJ, McPhail E, MacPhee GJA, Larkin JG, Gray JMD (1987) Psychomotor impairment and anticonvulsant therapy in adult epileptic patients. Eur J Clin Pharmacol 31: 655–660PubMedCrossRefGoogle Scholar
  10. 10.
    Connacher AA, Borsey DQ, Browning MCK et al. (1987) The effective evaluation of thyroid status in patients on phenytoin, carbamazepine or sodium valproate attending an epilepsy clinic. Postgrad Med 63: 841–845CrossRefGoogle Scholar
  11. 11.
    Curione M, land C, Manfredi M, Puletti M (1987) Sino-atrial block provoked by carbamazepine (Letter). J Neurol Neurosurg Psychiatry 50: 650–651PubMedCrossRefGoogle Scholar
  12. 12.
    Dodrill CB, Troupin AS (1991) Neuropsychological effects of carbamazepine and phenytoin: a re-analysis. Neurology 41: 141–143PubMedGoogle Scholar
  13. 13.
    Durelli L, Mutani R, Sechi GP, Monglo F, Glorioso N, Gusmasoli G (1985) Cardiac side effects of phenytoin and carbamazepine: a dose-related phenomenon. Arch Neurol 42: 1067–1068PubMedGoogle Scholar
  14. 14.
    Faigle JW, Feldmann KF (1989) Carbamazepine: Biotransformation. In: Levy R, Mattson R, Meldrum B, Penry JK, Dreifuss FE (eds) Antiepileptic drugs, 3rd edn. Raven Press, New York, pp 491–504Google Scholar
  15. 15.
    Gallassi R, Morreale A, Lorusso S, Procaccianti G, Lurgaresi E, Baruzzi A (1988) Carbamazepine and phenytoin: comparison of cognitive effects in epileptic patients during monotherapy and withdrawal. Arch Neurol 45: 892–994PubMedGoogle Scholar
  16. 16.
    Galeone D, Lamontanara G, Torelli D (1985) Acute hepatitis in a patient treated with carbamazepine. J Neurol 232: 301–303PubMedCrossRefGoogle Scholar
  17. 17.
    Gilhus NE, Lea T (1988) Carbamazepine: effect of IgG subclasses in epileptic patients. Epilepsia 29: 317–320PubMedCrossRefGoogle Scholar
  18. 18.
    Graves NM, Kriel RL, Jones-Saete C, Cloyd JC (1985) Relative bioavailability of rectally administered carbamazepine suspension in humans. Epilepsia 26: 429–437PubMedCrossRefGoogle Scholar
  19. 19.
    Herranz JL, Armijo JA, Arteaga R (1988) Clinical side effects of phenobarbital, primidone, phenytoin, carbamazepine and valproate during monotherapy in children. Epilepsia 29: 794–804PubMedCrossRefGoogle Scholar
  20. 20.
    Hewtson KA, Ritch AE, Watson RD (1986) Sick sinus syndrome aggravated by carbamazepine therapy for epilepsy. Postgrad Med 62: 497–498CrossRefGoogle Scholar
  21. 21.
    Horowitz S, Patwardhan R, Marcus E (1988) Hepatotoxic reactions associated with carbamazepine therapy. Epilepsia 29: 149–154PubMedCrossRefGoogle Scholar
  22. 22.
    Hruby K, Donner A, Jäger U (1985) Akute Selbstvergiftung mit Antiepileptika. Intensivmedizin 22: 168–171Google Scholar
  23. 23.
    Jacome DE (1987) Syncope and sudden death attributed to carbamazepine (Letter). J Neurol Neurosurg Psychiatry 50: 1245PubMedCrossRefGoogle Scholar
  24. 24.
    Johannessen AC, Nielsen OA (1986) Sinoatrial block, hyponatremia and urticaria caused by carbamazepine. Ugeskr Laeger 149: 376Google Scholar
  25. 25.
    Jones EX, Lacro RV, Johnson KA, Adams J (1989) Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 320: 1661–1666PubMedCrossRefGoogle Scholar
  26. 26.
    Kennebäck G, Bergfeldt L, Tomson T, Spina E, Edhag O (1992) Carbamazepine-induced bradycardia. Epilepsy Res 141–146Google Scholar
  27. 27.
    Lahr MB (1985) Hyponatremia during carbamazepine therapy. Clin Pharmacol Ther 37: 693–696PubMedCrossRefGoogle Scholar
  28. 28.
    Larrey D, Hadengue A, Pessayre D, Choudat L, Degott C, Benhamou JP (1987) Carbamazepine-induced acute cholangitis. Dig Dis Sci 32: 554–557PubMedCrossRefGoogle Scholar
  29. 29.
    Loiseau P, Cohadon S, Jogeix M, Legroux M, Dartigues JF (1984) Efficacité du valproate de sodium dans les épilepsies partielles: études croisée valproate-carbamazepine. Rev Neurol 140: 434–437PubMedGoogle Scholar
  30. 30.
    Mattson RH, Cramer JA, Collins JT (1992) A comparison of valproate and carbamazepine for the treatment of complex partial seizures and secondarity generalized tonic-clonic seizures in adults N Engl J Med 327 pp 765–771PubMedCrossRefGoogle Scholar
  31. 31.
    Mattson RH, Cramer JA, Collins JF et al. (1985) Comparison of carbamazepine, phenobarbital, Phenytoin and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 313: 1445–151CrossRefGoogle Scholar
  32. 32.
    Meador KJ, Loring DW, Huh K, Gallagher BB, King DW (1990) Comparative cognitive effects of anticonvulsants. Neurology 40: 381–394Google Scholar
  33. 33.
    Mitchell WG, Chavez JM (1987) Carbamazepine versus phenobarbital for partial onset seizures in children. Epilepsia 28: 56–60PubMedCrossRefGoogle Scholar
  34. 34.
    Muuronen A, Kaste M, Mikkila EA, Tolppanen EM (1985) Mortality from ischemic heart disease among patients using anticonvulsant drugs: a case-control study. Br Med J 291: 1481–1483CrossRefGoogle Scholar
  35. 35.
    Murphy JM, Mashman J, Miller JD, Bell JB (1991) Suppression of carbamazepine — induced rash with prednisone. Neurology 41: 144–145PubMedGoogle Scholar
  36. 36.
    Neuvonen PJ, Tokola O (1988) Bioavailability of rectally administered carbamazepine mixture. Br J Clin Pharmacol 24: 839–841Google Scholar
  37. 37.
    Nielsen NV, Syversen K (1986) Possible retinotoxic effect of carbamazepine. Acta Ophtalmol 64: 287–290CrossRefGoogle Scholar
  38. 38.
    O’Dougherty M, Wright FS, Cox S, Walson P (1987) Carbamazepine plasma concentration: relationship to cognitive impairment. Arch Neurol 44: 863–867PubMedGoogle Scholar
  39. 39.
    Post RM (1988) Time course of clinical effects of carbamazepine: implications for mechanisms of action. J Clin Psychiatry 49 [Suppl]: 35–48PubMedGoogle Scholar
  40. 40.
    Purves SJ, Hashimoto SA, Tse KS (1988) Successful desensitization of patients with carbamazepine allergy (Abstract). Epilepsia 29: 654Google Scholar
  41. 41.
    Reinikainen KJ, Keränen T, Halonen T, Komulainen H, Riekkinen PJ (1987) Comparison of ox-carbazepine and carbamazepine: a double-blind study. Epilepsy Res 1: 284–289PubMedCrossRefGoogle Scholar
  42. 42.
    Remy C (1990) Etude ouverte comparative de la carbamazepine et de la carbamazepine a libération prolongée dans l’épilepsie de l’adulte. Presse Med 19: 511–513PubMedGoogle Scholar
  43. 43.
    Ringel RA, Brick JF (1986) Perspective on carbamazepine-induced water intoxication: reversal by demeclocycline. Neurology 36: 1506–1507PubMedGoogle Scholar
  44. 44.
    Riva R, Contin M, Albani F et al. (1985) Lateral gaze nystagmus in carbamazepine treated epileptic patients: correlation with total and free plasma concentrations of parent drug and its 10, 11-epo-xide metabolite. Ther Drug Monit 7: 277–282PubMedCrossRefGoogle Scholar
  45. 45.
    Scoccia B, Scommegna A (1988) Carbamazepine-induced hyponatremia after transabdominal follicular ultrasound examination. Fertil Steril 50: 984–985PubMedGoogle Scholar
  46. 46.
    Schmidt D (1981) Effect of antiepileptic drugs on estrogens and progesterone metabolism and oral contraceptives. In: Dam M, Gram L, Penry JK (eds) Advances in epileptology: XIIth epilepsy international symposium. Raven Press, New York, pp 423–431Google Scholar
  47. 47.
    Schmidt D (1985) Adverse effects. In: Frey HH, Janz D (eds) Antiepileptic drugs. Springer, Berlin Heidelberg New York, pp 791–829CrossRefGoogle Scholar
  48. 48.
    Schmidt D (1992) Epilepsy in women. In: Laidlaw J, Richens A, Chadwick D (eds) A textbook of epilepsy, 4th edn. Churchill Livingstone Edinburgh, pp 645–660Google Scholar
  49. 49.
    Schmidt D (1992) Epilepsien und epileptische Anfälle. In: Kunze K (Hrsg) Lehrbuch der Neurologie. Thieme, Stuttgart, S 604–654Google Scholar
  50. 50.
    Schmidt D (1992) Vigabatrin. Intern Prax 32: 395–396Google Scholar
  51. 51.
    Schmidt D, Richter K (1986) Alternative single anticonvulsant drug therapy for refractory epilepsy. Ann Neurol 19: 85–87PubMedCrossRefGoogle Scholar
  52. 52.
    Schmidt D, Seldon L (1982) Adverse effect of antiepileptic drugs. Raven Press, New YorkGoogle Scholar
  53. 53.
    Schmidt D, Jacob R (1992) Clinical and laboratory monitoring of antiepileptic medication. In: Wyllie E (ed) The treatment of epilepsy: Principles and practice. Lea & Febiger, Philadelphia, pp 798–809Google Scholar
  54. 54.
    Schmidt D, Rohrer E (1992) Carbamazepine. In: Resor SR jr, Kutt H, (eds) The medical treatment of epilepsy. Dekker, New York, pp 293–306Google Scholar
  55. 55.
    Silvenius J, Heinonen E, Lehto H et al. (1988) Reduction of dosing frequency of carbamazepine with a slow-release preparation. Epilepsy Res 2: 32–36CrossRefGoogle Scholar
  56. 56.
    Smith DB, Mattson RH, Cramer JA et al. (1987) Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbital, Phenytoin and primidone. Epilepsia 28 [Suppl 3]: 50–58CrossRefGoogle Scholar
  57. 57.
    Snead OC, Hosey LC (1985) Exacerbation of seizures in children by carbamazepine. N Engl J Med 313: 916–921PubMedCrossRefGoogle Scholar
  58. 58.
    Soman M, Swenson C (1985) A possible case of carbamazepine-induced pancreatitis. Drug Intell Clin Pharm 19: 925–927PubMedGoogle Scholar
  59. 59.
    Theodore WH, Narang PK, Holmes MD, Reeves P, Nice FJ (1989) Carbamazepine and its epoxide: relation of plasma levels to toxicity and seizure control. Ann Neurol 25:194–196PubMedCrossRefGoogle Scholar
  60. 60.
    Tomson T, Nilsson BY, Levi R (1988) Impaired visual contrast sensitivity in epileptic patients treated with carbamazepine. Arch Neurol 45: 897–900PubMedGoogle Scholar
  61. 61.
    Tomson T, Almkvist O, Nilsson BY, Svensson J-O, Bertilsson L (1990) Carbamazepine-10, 11-epo-xide in epilepsy. A pilot study. Arch Neurol 47: 888–892PubMedGoogle Scholar
  62. 62.
    Trimble MR, Cull C (1988) Children of school age: the influence of antiepileptic drugs on behaviour and intellect. Epilepsia 29 [Suppl 3]: 15–19CrossRefGoogle Scholar
  63. 63.
    Ward DJ (1987) Carbamazepine-induced facial burns caused by a photocopier. Burns Incl Therm Inj 13: 322–324PubMedCrossRefGoogle Scholar
  64. 64.
    : Weaver DF, Camfield P, Fraser A (1988) Massive carbamazepine overdose: clinical and pharmacological observations in five episodes. Neurology 38: 755–759PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • D. Schmidt

There are no affiliations available

Personalised recommendations